Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Pseudomonas Infections

• Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
• A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
• Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
• Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
• Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
• Animal-Assisted Visitation Program Chlorhexidine Trial
• Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
• Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
• Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
• Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia
• Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
• Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease
• Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection
• The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas
• Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
• Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
• Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
• Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)
• Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
• Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
• Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa
• Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
• Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients
• Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
• Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
• OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
• Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
• Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
• Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
• Phase I Study of Colistin Methanesulfonate Sodium
• Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
• Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
• Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)
• Aztreonam Lysine for Pseudomonas Infection Eradication Study
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
• Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
• Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
• Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
• Second Open Label Extension to Bridging Study CTBM100C2303
• Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
• Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
• Open Label Extension to Bridging Study CTBM100C2303
• Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
• Comparison of Antibiotics for Pseudomonas in Early CF
• Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
• Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
• Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
• Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
• Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways
• Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
• Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
• Lcr35 / ICU / P. Aeruginosa
• Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia
• A Study of Ceftobiprole in Patients With Fever and Neutropenia.
• Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
• Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
• Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas
• Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
• Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis